<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02529774</url>
  </required_header>
  <id_info>
    <org_study_id>1507149-6</org_study_id>
    <nct_id>NCT02529774</nct_id>
  </id_info>
  <brief_title>Alternating Systemic and Hepatic Artery Infusion Therapy As Adjuvant Treatment After Resection of Liver Metastases From Colorectal Cancer</brief_title>
  <official_title>Efficacy and Safety of Alternating Systemic and Hepatic Artery Infusion Therapy Versus Systemic Chemotherapy Alone As Adjuvant Treatment After Resection of Liver Metastases From Colorectal Cancer: A Randomized, Parallel-Group, Open-Labelled, Active-Controlled Phase II/III Trial in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ye Xu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This adaptive seamless Phase II/III trial is to compare the efficacy and safety of adjuvant
      systemic chemotherapy (SCT) with or without hepatic arterial infusion (HAI) after complete
      hepatic resection for Chinese patients with metastatic colorectal cancer.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5-year</time_frame>
    <description>Overall survival will be measured from the date of randomization up to the date of death of any cause</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver Relapse-Free Survival Rate</measure>
    <time_frame>3-year</time_frame>
    <description>Liver Relapse-Free Survival (LRFS) is defined as the interval from the date of randomization to the date of liver localized metastatic relapse (with the exception of curatively treated non-melanoma skin cancer or carcinoma in situ of the cervix) or death from any cause whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>3-year</time_frame>
    <description>DFS is defined as the time interval from the date of randomization to the time of the first relapse at any site, death from any cause, or last recorded follow-up visit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">432</enrollment>
  <condition>Resected Liver Metastases From Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Systemic Chemotherapy plus Hepatic Artery Infusion (HAI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Systemic Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Floxuridine (FUDR),Dexamethasone (DXM), Heparin in combination with Oxaliplatin and Capecitabine (CapeOX) or in combination with Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)</intervention_name>
    <description>Hepatic Artery Infusion for four cycles:
Floxuridine (FUDR) 500mg/d, Day 1-2; DXM 1mg/day added to FUDR 2-day infusion; Heparin 1000U/day added to FUDR 2-day infusion
In combination with Systemic Chemotherapy CapeOX for 8 cycles:
Oxaliplatin 130 mg/m^2 iv over 2 hours, Day 1. Capecitabine 850mg/m^2/d PO Bid, given in the morning and evening, Day 1-14
Or in combination with Systemic Chemotherapy mFOLFOX6 for 12 cycles:
Oxaliplatin 85mg/m^2 IV over 2 hours, Day 1. Leucovorin 400mg/m^2 IV over 2 hours, Day 1 5-fluorouracil (FU) 400mg/m^2 IV and then 2400mg/m^2 over 48 hours IV continuous infusion. Day 1</description>
    <arm_group_label>Systemic Chemotherapy plus Hepatic Artery Infusion (HAI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin and Capecitabine (CapeOX) or Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)</intervention_name>
    <description>Systemic Chemotherapy CapeOX alone for 8 cycles:
Oxaliplatin 130 mg/m^2 iv over 2 hours, Day 1. Capecitabine 850mg/m^2/d PO Bid, given in the morning and evening, Day 1-14
Or Systemic Chemotherapy mFOLFOX6 alone for 12 cycles:
Oxaliplatin 85mg/m^2 IV over 2 hours, Day 1. Leucovorin 400mg/m^2 IV over 2 hours, Day 1 5-fluorouracil (FU) 400mg/m^2 IV and then 2400mg/m^2 over 48 hours IV continuous infusion. Day 1</description>
    <arm_group_label>Systemic Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Diagnosis Criteria:

        All patients should have histologically confirmed colorectal adenocarcinoma with hepatic
        metastases and primary tumours completely resected during the operation and with colorectal
        metastatic to the liver confirmed pathologically after the operation as well as with
        negative surgical margin.

        Main criteria for inclusion:

          -  Aged 18-75 years

          -  Diagnosed as colorectal adenocarcinoma which only spread to the liver and with no
             extra-hepatic metastases

          -  Prior curative resection of primary tumours (R0 resection) or concurrent feasible
             curative resection of primary tumours and hepatic metastases (R0 resection is met)

          -  Performance status ECOG 0-1

          -  No serious complication occurred during or after metastases resection and affected
             subsequent treatment.

          -  Hematology: White blood count ≧ 4.0X10^9/L, Absolute neutrophil count ≧1.5X10^9/L,
             Platelet count ≧ 100 X10^9/L, Hemoglobin ≧ 100g/L

          -  Blood biochemistry: Total bilirubin ≦2mg/dL , Direct bilirubin equal or less than 1.5
             times upper limit of normal (ULN), Alanine aminotransferase (ALT) no greater than 2.5
             times ULN, Aspartate aminotransferase (AST) no greater than 2.5 times ULN, Serum
             creatinine no greater than ULN, or glomerular filtration rate equal or greater than 60
             mL/min/1.73m^2

          -  Not pregnant or nursing at present

          -  Fertile patients must use effective contraception

          -  Able to withstand major operative procedure

          -  No prior or concurrent malignancy within the past 5 years except basal cell or
             squamous cell skin cancer or carcinoma in situ of any organ

          -  No prior hepatic artery infusion therapy with 5-FU or floxuridine

          -  No prior systemic chemotherapy for metastatic disease

          -  No other concurrent chemotherapy

          -  Able to understand and sign off informed consent form
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ye Xu, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University Shanghai Cancer Center China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ye Xu, Dr.</last_name>
    <phone>+86 21 64175590</phone>
    <email>xu_shirley021@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hongtu Zheng, Dr.</last_name>
    <phone>+86 180 1731 7711</phone>
    <email>zht5863@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center China</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ye Xu, Dr.</last_name>
      <phone>+86 21 64175590</phone>
      <email>xu_shirley021@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Hongtu Zheng, Dr.</last_name>
      <phone>+86 180 1731 7711</phone>
      <email>zht5863@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2015</study_first_submitted>
  <study_first_submitted_qc>August 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2015</study_first_posted>
  <last_update_submitted>August 18, 2015</last_update_submitted>
  <last_update_submitted_qc>August 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Ye Xu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Floxuridine</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

